Akums Drugs & Pharma
add_icon

Akums Drugs & Pharma

520.05
-1.30
(-0.25%)
Market Cap
8,185.27 Cr
PE Ratio
31.99
Volume
2,21,535.00
Day High - Low
525.45 - 516.60
52W High-Low
622.95 - 409.30
ann
There are new updates from the company1 day ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
8,185.27 Cr
EPS
16.67
PE Ratio
31.99
PB Ratio
2.47
Book Value
210.57
EBITDA
502.00
Dividend Yield
0.56 %
Industry
Healthcare
Return on Equity
11.22
Debt to Equity
0.17
Analyst Rating and Forecast
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
negative
Akums Drugs and subsidiary received ₹133.75 crore tax demands for FY18-25. Company states orders are unsustainable and will appeal.
positive
Akums Drugs Q4 FY26 Adj EBITDA up 61.6% YoY to ₹152 crore; FY26 revenue ₹4,359 crore, +5.9% YoY. CDMO revenue ₹952 crore in Q4. Board declares ₹3/share dividend.
negative
Akums Drugs & Pharma reports temporary disruption at Haridwar manufacturing sites due to labour unrest at SIDCUL industrial area on May 14, 2026.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,844.60
#1 4,42,581.33
41.43
#1 54,729.00
9.71
#1 10,980
16.07
54.75
6,887.00
1,82,828.21
73.47
9,712.00
18.67
2,191
-1.02
66.48
4,486.20
1,51,833.39
66.60
11,539.40
6.99
1,911
26.24
61.90
1,399.20
1,13,024.67
29.32
27,711.70
-2.46
3,783
-55.32
61.92
1,307.20
1,09,104.54
26.47
33,593.30
-0.44
3,998
-86.05
52.61
1,038.95
1,04,542.68
20.35
26,719.70
13.65
5,242
7.82
69.40
2,281.80
1,04,288.12
#1 19.51
27,487.50
19.98
5,345
#1 87.72
47.33
2,479.40
1,02,350.89
53.58
14,277.60
12.03
1,750
31.75
62.34
1,463.50
85,000.32
25.77
32,345.60
9.43
3,484
1.99
52.91
1,343.50
72,529.73
81.91
6,812.90
#1 21.03
884
21.18
77.10
Growth Rate
Revenue Growth
4.53 %
Net Income Growth
-14.99 %
Cash Flow Change
-6.64 %
ROE
10,100.00 %
ROCE
5,030.43 %
EBITDA Margin (Avg.)
-9.69 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Revenue
978
1,188
1,093
955
1,026
1,050
1,030
1,081
1,051
1,050
1,194
1,193
Expenses
1,095
1,057
989
941
891
912
889
962
895
923
1,031
1,008
EBITDA
-117
131
103
14
135
138
141
120
156
127
163
185
Operating Profit %
-13 %
11 %
9 %
0 %
13 %
12 %
12 %
9 %
13 %
9 %
11 %
13 %
Depreciation
30
30
32
34
34
35
45
40
37
38
40
40
Interest
12
14
12
12
13
12
5
5
23
23
24
24
Profit Before Tax
-159
87
59
-33
88
92
91
75
96
66
100
121
Tax
29
54
-136
7
26
25
25
-75
31
23
32
40
Net Profit
-187
33
195
-40
61
67
66
150
65
43
68
81
EPS in ₹
-13.16
2.22
13.21
-2.89
4.21
4.37
4.26
9.64
4.15
2.66
4.33
5.53

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
2025
2026
Total Assets
2,078
2,167
3,069
3,267
3,516
4,113
5,447
Fixed Assets
645
904
1,021
1,097
1,191
1,397
1,631
Current Assets
1,250
1,157
1,864
1,879
1,941
2,275
3,560
Capital Work in Progress
57
17
31
103
195
163
177
Investments
6
20
0
0
0
0
756
Other Assets
1,371
1,226
2,017
2,066
2,130
2,553
0
Total Equity & Liabilities
2,078
2,167
3,069
3,267
3,516
4,113
5,447
Current Liabilities
730
580
1,272
1,266
1,211
894
1,095
Non Current Liabilities
627
700
1,172
1,278
1,585
156
1,021
Total Equity
721
887
625
723
721
3,064
3,313
Reserve & Surplus
721
884
608
689
681
3,016
3,283
Share Capital
1
1
14
29
29
31
31

Cash Flow

Cash Flow
2015
2016
2020
2021
2022
2023
2024
2025
Net Cash Flow
-11
4
71
-70
33
-4
59
-10
Investing Activities
-150
-123
-190
-109
-235
-305
-331
-548
Operating Activities
72
89
28
131
32
177
498
465
Financing Activities
66
37
233
-92
236
125
-108
73

Share Holding

% Holding
Feb 2024
Aug 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Promoter
84.91 %
75.26 %
75.26 %
75.26 %
75.26 %
75.26 %
75.26 %
75.26 %
75.26 %
FIIs
0.00 %
5.32 %
7.34 %
6.36 %
5.77 %
4.24 %
2.28 %
1.15 %
1.37 %
DIIs
0.00 %
7.60 %
7.52 %
7.00 %
7.40 %
8.85 %
9.28 %
14.40 %
14.35 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
4.43 %
2.11 %
3.33 %
3.41 %
3.60 %
5.01 %
5.51 %
5.34 %
Others
15.09 %
7.38 %
7.77 %
8.05 %
8.16 %
8.05 %
8.18 %
3.68 %
3.68 %
No of Share Holders
8
1,38,205
57,531
68,410
69,366
69,424
75,365
76,869
72,589

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
10 Jul 2026 ANNUAL GENERAL MEETING Annual General Meeting
NA
10 Jul 2026 540.95 520.05
09 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
09 Nov 2024 845.30 796.60
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 566.55 570.30
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 May 2025 546.50 566.05
18 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
18 Jul 2025 566.05 559.90
08 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 Aug 2025 513.90 490.80
13 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Nov 2025 454.45 453.15
13 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Feb 2026 439.55 464.00
14 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 May 2026 557.10 540.95

Announcements

Receipt Of Assessment Order(S) By Certain Subsidiaries From Income Tax Department1 day ago
Announcement under Regulation 30 (LODR)-Earnings Call Transcript2 days ago
Receipt Of Assessment Order(S) From Income Tax Department3 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome5 days ago
Update On Disruption In Operations At Some Of The Manufacturing Sites At Haridwar5 days ago
Compliances-Reg.24(A)-Annual Secretarial Compliance7 days ago
Update On Disruption In Operations At Some Of The Manufacturing Sites At Haridwar7 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication8 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation9 days ago
Announcement under Regulation 30 (LODR)-Monitoring Agency Report9 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release9 days ago
Intimation Of Disruption In Operations At Some Of The Manufacturing Sites At Haridwar9 days ago
Corporate Action-Board approves Dividend9 days ago
Announcement under Regulation 30 (LODR)-Change in Management9 days ago
Announcement under Regulation 30 (LODR)-Change in Management9 days ago
Announcement under Regulation 30 (LODR)-Change in Management9 days ago
Financial Results For The Quarter And Year Ended 31St March 20269 days ago
Recommendation Of Final Cum Special Dividend9 days ago
Board Meeting Outcome for Outcome Of Board Meeting For Financial Results9 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
Board Meeting Intimation for Board Meeting IntimationMay 11, 2026
ESG RatingMay 08, 2026
Execution Of Lease DeedApr 29, 2026
Announcement under Regulation 30 (LODR)-Credit RatingApr 11, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 04, 2026
Closure of Trading WindowMar 23, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 26, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 19, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 16, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 14, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 13, 2026
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 13, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 13, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 13, 2026
Approval Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31.12.2025Feb 13, 2026
Board Meeting Outcome for Outcome Of Board Meeting Held On 13Th February 2026Feb 13, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 31, 2026
Board Meeting Intimation for Consider And Approve The Un-Audited (Standalone & Consolidated) Financial Results For The Quarter And Nine Months Ended On 31St December 2025.Jan 31, 2026
EU-GMP CertificationJan 23, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2026
Resignation Of Senior Management PersonnelDec 27, 2025
Closure of Trading WindowDec 27, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Dec 22, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Dec 22, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - UpdateDec 16, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Dec 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 17, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 17, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 14, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
JioBlackRock Flexi Cap Fund Direct-Growth
0.42%
93594
0.17%
0.33%
Old Bridge Flexi Cap Fund Direct-Growth
2.73%
76000
2.73%
2.73%
Franklin India Multi-Factor Fund Direct-Growth
0.30%
21480
0.22%
0.30%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.01%
5
0.00%
0.00%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth
2.02%
0
0.00%
0.20%
PGIM India Small Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.01%
0
0.00%
0.00%
Bandhan Small Cap Fund Direct-Growth
0.38%
0
0.00%
-0.02%
DSP Nifty 500 Index Fund Direct-Growth
0.00%
0
0.00%
-0.01%
DSP Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
0
0.00%
-0.07%
Edelweiss Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
Edelweiss Recently Listed IPO Fund Direct-Growth
0.00%
0
0.00%
0.00%
Franklin India Multi Cap Fund Direct-Growth
1.37%
0
0.00%
0.05%
Axis Nifty 500 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
Franklin India Opportunities Direct Fund-Growth
1.62%
0
0.00%
0.00%
JM Small Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Groww Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
Groww Nifty Total Market Index Fund Direct-Growth
0.01%
0
0.00%
0.00%
Groww Value Fund Direct-Growth
0.00%
0
0.00%
0.00%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
ICICI Prudential ELSS Tax Saver Direct Plan-Growth
0.68%
0
0.00%
0.05%
ICICI Prudential Equity & Debt Fund Direct-Growth
0.12%
0
0.00%
0.01%
ICICI Prudential Multi Asset Fund Direct-Growth
0.11%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
47.86
ATR(14)
Less Volatile
20.87
STOCH(9,6)
Neutral
27.72
STOCH RSI(14)
Oversold
7.10
MACD(12,26)
Bearish
-4.93
ADX(14)
Weak Trend
23.68
UO(9)
Bearish
44.04
ROC(12)
Downtrend And Accelerating
-5.69
WillR(14)
Neutral
-68.19

About Akums Drugs & Pharma

Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) established in 2004. The company offers a wide range of pharmaceutical products and services both domestically and internationally. Their operations include manufacturing of Active Pharmaceutical Ingredients (APIs), sale of branded pharmaceutical formulations, formulation research and...more
Listing Date
06 Aug, 2024(1 Years, 47 days)